CEO Chris Chen on Wednesday told the J.P. Morgan Healthcare Conference in San Francisco the China-headquartered CRDMO is scaling global manufacturing capacity.
A pilot program shows reaction data that can compress active pharmaceutical ingredient process development timelines from years to months, according to the companies.